Radiopharm Theranostics (NASDAQ:RADX) Coverage Initiated by Analysts at HC Wainwright

Stock analysts at HC Wainwright initiated coverage on shares of Radiopharm Theranostics (NASDAQ:RADX) in a research note issued to investors on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $16.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 256.35% from the stock’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $16.00.

Radiopharm Theranostics Stock Down 1.3%

Radiopharm Theranostics stock opened at $4.49 on Thursday. Radiopharm Theranostics has a 1-year low of $3.62 and a 1-year high of $16.25. The company has a fifty day simple moving average of $4.48 and a 200 day simple moving average of $4.80.

Institutional Investors Weigh In On Radiopharm Theranostics

A number of institutional investors and hedge funds have recently modified their holdings of RADX. Hsbc Holdings PLC bought a new stake in shares of Radiopharm Theranostics during the 4th quarter worth about $1,007,000. Virtu Financial LLC bought a new stake in shares of Radiopharm Theranostics during the 4th quarter worth about $76,000. Jane Street Group LLC bought a new stake in shares of Radiopharm Theranostics during the 4th quarter worth about $76,000. Marex Group plc bought a new stake in shares of Radiopharm Theranostics during the 4th quarter worth about $54,000. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Radiopharm Theranostics by 100.0% during the 3rd quarter. PNC Financial Services Group Inc. now owns 16,000 shares of the company’s stock worth $88,000 after buying an additional 8,000 shares during the period.

About Radiopharm Theranostics

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.